SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+39.29%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$646M
AUM Growth
+$646M
(+0.56%)
Cap. Flow
-$249M
Cap. Flow
% of AUM
-38.48%
Top 10 Holdings %
Top 10 Hldgs %
76.2%
Holding
43
New
2
Increased
4
Reduced
3
Closed
4
Top Buys
| 1 |
Jasper Therapeutics
JSPR
|
$15.4M |
| 2 |
Nkarta
NKTX
|
$9.73M |
| 3 |
Mineralys Therapeutics
MLYS
|
$7.17M |
| 4 |
Adverum Biotechnologies
ADVM
|
$4.12M |
| 5 |
vTv Therapeutics
VTVT
|
$3.9M |
Top Sells
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
$162M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$115M |
| 3 |
Janux Therapeutics
JANX
|
$6.78M |
| 4 |
PepGen
PEPG
|
$2.97M |
| 5 |
RAIN
Rain Oncology Inc. Common Stock
RAIN
|
$2.44M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$3.14B
| $121M | 18.65% | 6,788,609 | – | – |
|
|
CRGX
2
DELISTED
CARGO Therapeutics
CRGX
| $92M | 14.23% | 4,121,689 | – | – |
|
|
3
Mineralys Therapeutics
MLYS
$1.03B
| $65.5M | 10.14% | 5,074,916 +555,555 | +12% | +$7.17M |
|
4
Neurogene
NGNE
$264M
| $64.5M | 9.98% | 1,267,790 | – | – |
|
|
5
Nkarta
NKTX
$151M
| $40.7M | 6.3% | 3,768,035 +900,000 | +31% | +$9.73M |
|
6
Arcellx
ACLX
$3.85B
| $31.6M | 4.88% | 453,641 -6,800 | -1% | -$473K |
|
|
LENZ
7
LENZ Therapeutics
LENZ
$1.1B
| $27M | 4.17% | 1,208,473 -7,250,841 | -86% | -$162M |
|
8
Lyra Therapeutics
LYRA
$11.5M
| $17.3M | 2.68% | 2,780,261 | – | – |
|
|
SLRN
9
DELISTED
ACELYRIN
SLRN
| $17M | 2.63% | 2,523,022 | – | – |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.43B
| $16.3M | 2.53% | 967,527 | – | – |
|
|
11
Jasper Therapeutics
JSPR
$45.5M
| $15.4M | 2.38% | +525,000 | New | +$15.4M |
|
12
Zymeworks
ZYME
$1.12B
| $15.3M | 2.37% | 1,458,875 | – | – |
|
13
HilleVax
HLVX
$105M
| $13.3M | 2.06% | 799,274 | – | – |
|
|
ABVX
14
Abivax
ABVX
$6.12B
| $12.2M | 1.88% | 850,000 | – | – |
|
|
INZY
15
DELISTED
Inozyme Pharma
INZY
| $12M | 1.85% | 1,562,500 | – | – |
|
|
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $9.56M | 1.48% | 1,786,427 | – | – |
|
17
Sutro Biopharma
STRO
$72.7M
| $9.47M | 1.46% | 1,675,579 | – | – |
|
18
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.48M | 1.16% | 172,647 | – | – |
|
19
Gossamer Bio
GOSS
$562M
| $7.23M | 1.12% | 6,130,268 | – | – |
|
|
20
Janux Therapeutics
JANX
$1.37B
| $6.78M | 1.05% | 180,207 -180,207 | -50% | -$6.78M |
|
21
IO Biotech
IOBT
$104M
| $6.3M | 0.97% | 3,640,015 | – | – |
|
|
VRNA
22
Verona Pharma
VRNA
$9.16B
| $5.59M | 0.87% | 347,500 | – | – |
|
23
Tango Therapeutics
TNGX
$747M
| $5M | 0.77% | 630,000 | – | – |
|
|
24
vTv Therapeutics
VTVT
| $4.87M | 0.75% | 206,784 +165,896 | +406% | +$3.9M |
|
25
Immatics
IMTX
$619M
| $4.16M | 0.64% | 396,000 | – | – |
|